Receipt of R&D tax refund for FY2024
Filed with ASX · · 2 pages · English
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Clinical trial progress update
- Island completes $3.5m Placement
- Phase 2a PROTECT clinical trial dosed & Investor webinar
- Binding LOI for proposed acquisition of Galidesivir
- ISLA-101 Phase 2a/b clinical trial progresses
Later from Island Pharmaceuticals
- ISLA-101 shows anti-dengue activity in Phase 2a readout
- US patent granted for ISLA-101
- ISLA-101 Phase 2b clinical trial enrols first subjects
- Completion of enrolment in Phase 2b arm
- Completion of patient dosing in Phase 2b clinical trial
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals